Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Rating of “Moderate Buy” from Brokerages

Roivant Sciences Ltd. (NASDAQ:ROIV) has been given a consensus recommendation of “Moderate Buy” by the eight research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $17.93.

Separately, HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a research report on Wednesday, November 13th.

Insiders Place Their Bets

In other Roivant Sciences news, CIO Mayukh Sukhatme sold 412,584 shares of the company’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $12.05, for a total value of $4,971,637.20. Following the transaction, the executive now owns 18,836,547 shares in the company, valued at approximately $226,980,391.35. This represents a 2.14 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Eric Venker sold 100,000 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $11.28, for a total transaction of $1,128,000.00. Following the completion of the sale, the chief operating officer now owns 732,294 shares of the company’s stock, valued at approximately $8,260,276.32. The trade was a 12.01 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,942,629 shares of company stock worth $23,034,486 over the last ninety days. 7.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Roivant Sciences

A number of hedge funds have recently modified their holdings of ROIV. GAMMA Investing LLC boosted its holdings in Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after purchasing an additional 1,288 shares in the last quarter. Covestor Ltd raised its holdings in Roivant Sciences by 9.1% during the third quarter. Covestor Ltd now owns 19,190 shares of the company’s stock valued at $222,000 after buying an additional 1,605 shares in the last quarter. US Bancorp DE lifted its position in shares of Roivant Sciences by 146.5% in the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after buying an additional 1,948 shares during the last quarter. Quarry LP boosted its stake in shares of Roivant Sciences by 50.0% during the 3rd quarter. Quarry LP now owns 7,500 shares of the company’s stock worth $87,000 after acquiring an additional 2,500 shares in the last quarter. Finally, Gladius Capital Management LP acquired a new position in shares of Roivant Sciences during the 3rd quarter valued at about $35,000. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Price Performance

Shares of ROIV stock opened at $11.15 on Tuesday. The firm has a fifty day moving average of $11.74 and a two-hundred day moving average of $11.61. The firm has a market cap of $8.11 billion, a P/E ratio of 1.97 and a beta of 1.27. Roivant Sciences has a 1-year low of $9.69 and a 1-year high of $13.06.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.